Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
This study has been completed.
Ohio State University Comprehensive Cancer Center
Pharmacia and Upjohn
Information provided by (Responsible Party):
Miguel Villalona, Ohio State University Comprehensive Cancer Center
First received: September 12, 2005
Last updated: December 18, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||February 2010|
|Primary Completion Date:||October 2006 (Final data collection date for primary outcome measure)|
Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol. 2010 May;5(5):713-8. doi: 10.1097/JTO.0b013e3181d7776d.